[抗人原发性肝癌单克隆抗体（Hepama I）在患者中的放射免疫靶向与治疗]
[Radioimmunologic targeting and therapy with antihuman primary hepatic cancer monoclonal antibodies (Hepama I) in patients].
作者信息
Shi L, Wu M, Chen H
机构信息
Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai.
出版信息
Zhonghua Zhong Liu Za Zhi. 1997 Mar;19(2):146-9.
OBJECTIVE
Effects of monoclonal antibody Hepama-I on targeting and therapy for primary hepatic cancer (PHC) were studied.
METHODS
Thirty patients with veritified unresectable PHC were included in this study. For radioimmunoimaging (RII), 131I hepama was administered to 18 patients at a mean dose of 9.25 GBq. For radioimmunotherapy (RIT), 12 patients received a mean dose of 18.5 GBq by Seldinger's method via the hepatic artery.
RESULTS
The optimum imaging time was 96 hours after injection. A decline in AFP level was found in 6/8 (75.0%). Reduction of tumor volume was observed as PR 66.6% and the survival time was prolonged in groups with 131I-Hepama-I treatment.
CONCLUSION
Hepama I can recognized PHC cells in vivo and intra-hepatic arterial infusion of 131I-Hepama I is one of the acceptable methods of multimodality treatment for unresectable primary hepatic cancer in man.
目的
研究单克隆抗体Hepama-I对原发性肝癌（PHC）的靶向及治疗作用。
方法
本研究纳入30例经证实无法切除的PHC患者。对于放射免疫显像（RII），18例患者接受131I-Hepama，平均剂量为9.25GBq。对于放射免疫治疗（RIT），12例患者通过Seldinger法经肝动脉接受平均剂量为18.5GBq的治疗。
结果
最佳显像时间为注射后96小时。8例中有6例（75.0%）甲胎蛋白（AFP）水平下降。观察到肿瘤体积缩小，部分缓解（PR）率为66.6%，131I-Hepama-I治疗组的生存时间延长。
结论
Hepama I可在体内识别PHC细胞，肝动脉内注入131I-Hepama I是对无法切除的人类原发性肝癌进行多模式治疗的可接受方法之一。
Zotero 插件